Catalyst Wire Dossier Catalyst Wire Dossier

FOV2302

ecallantide · Fovea Pharmaceuticals SA
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FOV2302, covering 2012-01-10 to 2012-01-10. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion [Phase 1]

See pricing